Fingerprint
Dive into the research topics of 'Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Ahmed O. Kaseb, Jeffrey S. Morris, Michiko Iwasaki, Humaid O. Al-Shamsi, Kanwal Pratap Singh Raghav, Lauren Girard, Sheree Cheung, Van Nguyen, Khaled M. Elsayes, Lianchun Xiao, Reham Abdel-Wahab, Ahmed S. Shalaby, Manal Hassan, Hesham M. Hassabo, Robert A. Wolff, James C. Yao
Research output: Contribution to journal › Article › peer-review
21
Scopus
citations